Avadel Pharmaceuticals (AVDL) Receivables (2016 - 2020)
Historic Receivables for Avadel Pharmaceuticals (AVDL) over the last 12 years, with Q4 2020 value amounting to $1.4 million.
- Avadel Pharmaceuticals' Receivables fell 8645.81% to $1.4 million in Q4 2020 from the same period last year, while for Dec 2020 it was $1.4 million, marking a year-over-year decrease of 8645.81%. This contributed to the annual value of $1.4 million for FY2020, which is 8645.81% down from last year.
- According to the latest figures from Q4 2020, Avadel Pharmaceuticals' Receivables is $1.4 million, which was down 8645.81% from $7.3 million recorded in Q2 2020.
- Avadel Pharmaceuticals' 5-year Receivables high stood at $24.1 million for Q3 2017, and its period low was $1.4 million during Q4 2020.
- Over the past 5 years, Avadel Pharmaceuticals' median Receivables value was $15.4 million (recorded in 2016), while the average stood at $14.1 million.
- Per our database at Business Quant, Avadel Pharmaceuticals' Receivables skyrocketed by 103477.83% in 2016 and then tumbled by 8645.81% in 2020.
- Avadel Pharmaceuticals' Receivables (Quarter) stood at $17.8 million in 2016, then decreased by 17.12% to $14.8 million in 2017, then increased by 18.78% to $17.6 million in 2018, then crashed by 42.47% to $10.1 million in 2019, then crashed by 86.46% to $1.4 million in 2020.
- Its Receivables stands at $1.4 million for Q4 2020, versus $7.3 million for Q2 2020 and $8.8 million for Q1 2020.